Clinical Trial Update: Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing teriflunomide for relapsing multiple sclerosis has completed, with reported safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Teriflunomide (teriflunomide)

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED